What's in Neurimmune AG's pipeline?

Neurimmune AG has 2 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Neurimmune AG's portfolio?

Top competitors by shared drug class: Alexion Pharmaceuticals, Inc., Amgen, Arbeitsgemeinschaft medikamentoese Tumortherapie, Assistance Publique - Hôpitaux de Paris, Azienda Ospedaliera Universitaria Integrata Verona.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/neurimmune-ag.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Neurimmune AG — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neurimmune AG pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
ALXN2220	ALXN2220	phase 3	Monoclonal antibody	Phosphatidylserine	Neurology

Therapeutic area mix

Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Alexion Pharmaceuticals, Inc. · 1 shared drug class
Amgen · 1 shared drug class
Arbeitsgemeinschaft medikamentoese Tumortherapie · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Azienda Ospedaliera Universitaria Integrata Verona · 1 shared drug class
Baxalta now part of Shire · 1 shared drug class
Bayer · 1 shared drug class
AgeneBio · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Neurimmune AG:

Cite this brief

Drug Landscape (2026). Neurimmune AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/neurimmune-ag. Accessed 2026-06-10.